Julie Ann Justo

List of Publications by Year
in descending order

69	1,108	430874 18	454955 30
papers	citations	h-index	g-index

69	69	69	1585
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An experiential learning collaborative on quality improvement for interprofessional learners. Journal of Interprofessional Care, 2022, 36, 327-330.	1.7	2
2	Evaluation of early clinical failure criteria in Enterococcus species bloodstream infection. Infection, 2022, 50, 873-877.	4.7	3
3	How to Harness the Power of Social Media for Quality Drug Information in Infectious Diseases: Perspectives on Behalf of the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases, 2022, 74, e23-e33.	5.8	1
4	Prediction of mortality in Staphylococcus aureus bloodstream infection using quick Pitt bacteremia score. Journal of Infection, 2022, 84, 131-135.	3.3	14
5	Temporal Association between Influenza Vaccination Coverage and Ambulatory Antibiotic Use in Children. Pediatric Infectious Disease Journal, 2022, 41, 600-602.	2.0	5
6	Clinical Utility and Cost Effectiveness of Long-Acting Lipoglycopeptides Used in Deep-Seated Infections among Patients with Social and Economic Barriers to Care. Pharmacy (Basel, Switzerland), 2022, 10, 1.	1.6	7
7	Show me the data: A statewide comparative report of National Healthcare Safety Network (NHSN) Antimicrobial Use Option standardized antimicrobial administration ratios (SAARs). Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	3
8	Regional and statewide antibiograms as targeted interventions against antibiotic resistance. Infection Control and Hospital Epidemiology, 2021, 42, 503-505.	1.8	1
9	Clostridioides difficile infection and antibiotic prescription rates in the community: Explaining the gender gap. Infection Control and Hospital Epidemiology, 2021, 42, 622-624.	1.8	2
10	Application of Standardized Antimicrobial Administration Ratio as a Motivational Tool within a Multi-Hospital Healthcare System. Pharmacy (Basel, Switzerland), 2021, 9, 32.	1.6	6
11	Investing in the Future: A Role for Professional Societies to Prepare the Next Generation of Healthcare Leaders Through Curriculum Development and Dissemination. Clinical Infectious Diseases, 2021, 73, 911-918.	5.8	1
12	Impact of follow up blood cultures on outcomes of patients with community-onset gram-negative bloodstream infection. EClinicalMedicine, 2021, 34, 100811.	7.1	14
13	Evaluation of the Infectious Diseases Society of Americaâ€™s Core Antimicrobial Stewardship Curriculum for Infectious Diseases Fellows. Clinical Infectious Diseases, 2021, , .	5.8	6
14	Change in Antimicrobial Use During COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study. International Journal of Antimicrobial Agents, 2021, 58, 106453.	2.5	16
15	Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infectious Diseases, 2021, 8, ofab554.	0.9	18
16	Evaluation of early clinical failure criteria for gram-negative bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 73-77.	6.0	20
17	Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study. Infection, 2020, 48, 129-132.	4.7	9
18	Prediction of trimethoprim/sulfamethoxazole resistance in community-onset urinary tract infections. Journal of Global Antimicrobial Resistance, 2020, 21, 218-222.	2.2	13

#	Article	IF	Citations
19	Empirical fluoroquinolones versus broad-spectrum beta-lactams for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors. Journal of Global Antimicrobial Resistance, 2020, 22, 87-93.	2.2	5
20	Evaluating appropriateness and diagnostic stewardship opportunities of multiplex polymerase chain reaction gastrointestinal testing within a hospital system. Therapeutic Advances in Infectious Disease, 2020, 7, 204993612095956.	1.8	7
21	Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature. International Journal of Antimicrobial Agents, 2020, 56, 106158.	2.5	22
22	Regulatory Approval, Implementation, and Brief Assessment of a Pharmacist- and Pharmacy Trainee-Administered Penicillin Allergy Assessment and Skin Testing Program. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1269.	1.0	9
23	Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia, and Citrobacter Species. Antibiotics, 2020, 9, 254.	3.7	12
24	Temporal trends in ambulatory antibiotic prescription rates in South Carolina: Impact of age, gender, and resident location. Infection Control and Hospital Epidemiology, 2020, 41, 879-882.	1.8	3
25	Pharmacist-Driven Culture and Sexually Transmitted Infection Testing Follow-Up Program in the Emergency Department. Pharmacy (Basel, Switzerland), 2020, 8, 72.	1.6	8
26	Recommended Revisions to the National SEPâ€1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. Pharmacotherapy, 2020, 40, 368-371.	2.6	1
27	Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates. Antibiotics, 2020, 9, 189.	3.7	5
28	Motivational Application of Standardized Antimicrobial Administration Ratios Within a Healthcare System. Infection Control and Hospital Epidemiology, 2020, 41, s321-s321.	1.8	0
29	Ignoring the Elephant: Does the Infectious Diseases Society of America Support Sepsis-3 or Pre-sepsis Criteria?. Clinical Infectious Diseases, 2019, 68, 1431-1431.	5.8	5
30	Direct Measurement of Performance: A New Era in Antimicrobial Stewardship. Antibiotics, 2019, 8, 127.	3.7	19
31	Penicillin Allergy Skin Testing in the Inpatient Setting. Pharmacy (Basel, Switzerland), 2019, 7, 120.	1.6	10
32	Penicillin Allergy Assessment and Skin Testing in the Outpatient Setting. Pharmacy (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td	1.6	15
33	A practical guide for pharmacists to successfully implement penicillin allergy skin testing. American Journal of Health-System Pharmacy, 2019, 76, 136-147.	1.0	31
34	Syndrome-specific versus prospective audit and feedback interventions for reducing use of broad-spectrum antimicrobial agents. American Journal of Infection Control, 2019, 47, 1284-1289.	2.3	12
35	Seasonal variation in antimicrobial resistance rates of community-acquired Escherichia coli bloodstream isolates. International Journal of Antimicrobial Agents, 2019, 54, 1-7.	2.5	18
36	Use of continuous infusion ceftolozaneâ€“tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. American Journal of Health-System Pharmacy, 2019, 76, 501-504.	1.0	20

#	Article	IF	Citations
37	Utility of Combination Antimicrobial Therapy in Adults with Bloodstream Infections due to Enterobacteriaceae and Non-Fermenting Gram-Negative Bacilli Based on In Vitro Analysis at Two Community Hospitals. Antibiotics, 2019, 8, 15.	3.7	6
38	2733. Association Between Influenza Vaccination Coverage and Ambulatory Antibiotic Prescription Rates in Children in South Carolina. Open Forum Infectious Diseases, 2019, 6, S962-S962.	0.9	1
39	Association Between Body Mass Index and Mortality in Patients With Gram-Negative Bloodstream Infections. Infectious Diseases in Clinical Practice, 2019, 27, 90-95.	0.3	1
40	Role of Early De-escalation of Antimicrobial Therapy on Risk of Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream Infections. Clinical Infectious Diseases, 2019, 69, 414-420.	5.8	35
41	Antimicrobial Stewardship Training for Infectious Diseases Fellows: Program Directors Identify a Curriculum Need. Clinical Infectious Diseases, 2018, 67, 1285-1287.	5.8	24
42	Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection. Infection, 2018, 46, 283-284.	4.7	2
43	Duration of Antimicrobial Therapy for Enterobacteriaceae Bacteremia: Using Convenient End Points for Convenient Conclusions. Clinical Infectious Diseases, 2018, 66, 1978-1979.	5.8	5
44	Impact of Penicillin Allergy on Empirical Carbapenem Use in Gramâ€Negative Bloodstream Infections: An Antimicrobial Stewardship Opportunity. Pharmacotherapy, 2018, 38, 42-50.	2.6	23
45	Combination therapy vs. monotherapy for Gram-negative bloodstream infection: matching by predicted prognosis. International Journal of Antimicrobial Agents, 2018, 51, 488-492.	2.5	8
46	975. Clostridium difficile Infection and Antibiotic Prescription Rates in the Community: Explaining the Gender Gap. Open Forum Infectious Diseases, 2018, 5, S39-S39.	0.9	1
47	Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible Escherichia coli: A Missed Opportunity for De-Escalation of Therapy. Antibiotics, 2018, 7, 104.	3.7	2
48	Minimum Acceptable Susceptibility of Empirical Antibiotic Regimens for Gram-Negative Bloodstream Infections. Infectious Diseases in Clinical Practice, 2018, 26, 283-287.	0.3	6
49	Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a caseâ€“caseâ€“control study. Infection, 2018, 46, 487-494.	4.7	12
50	Preventing the Post-Antibiotic Era by Training Future Pharmacists as Antimicrobial Stewards. American Journal of Pharmaceutical Education, 2018, 82, 6770.	2.1	22
51	Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
52	Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection, 2017, 45, 613-620.	4.7	54
53	Clinical Risk Score for Prediction of Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae in Bloodstream Isolates. Infection Control and Hospital Epidemiology, 2017, 38, 266-272.	1.8	66
54	Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence. Hospital Pharmacy, 2017, 52, 691-697.	1.0	16

#	Article	IF	Citations
55	Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 299-304.	3.0	54
56	Differential effect of prior Î²-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2017, 87, 87-91.	1.8	22
57	Pharmacokinetic Assessment of Continuous Infusion Ceftolozane/Tazobactam for Drug-Resistant Pseudomonas aeruginosa Left Ventricular Assist Device Driveline Infection. Open Forum Infectious Diseases, 2017, 4, S282-S283.	0.9	1
58	Association Between Body Mass Index and Mortality in Gram-Negative Bloodstream Infections. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
59	Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections. International Journal of Antimicrobial Agents, 2016, 48, 498-503.	2.5	63
60	Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae. American Journal of Infection Control, 2016, 44, 1611-1616.	2.3	11
61	Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 2265-2272.	3.2	32
62	Staphylococcus aureus Infection of the Optic Nerve. Journal of Neuro-Ophthalmology, 2015, 35, 48-50.	0.8	3
63	Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 3956-3965.	3.2	27
64	Adverse Reactions Associated with Systemic Polymyxin Therapy. Pharmacotherapy, 2015, 35, 28-33.	2.6	100
65	Knowledge and Attitudes of Doctor of Pharmacy Students Regarding the Appropriate Use of Antimicrobials. Clinical Infectious Diseases, 2014, 59, S162-S169.	5.8	62
66	Antibiotic lock therapy: review of technique and logistical challenges. Infection and Drug Resistance, 2014, 7, 343.	2.7	75
67	Commentary on â€œIncidence and Predictors of Vancomycin-Associated Nephrotoxicityâ€• Southern Medical Journal, 2014, 107, 389-390.	0.7	1
68	Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Therapeutic Advances in Respiratory Disease, 2013, 7, 272-287.	2.6	14
69	Assessment of antimicrobial pharmacokinetics curricula across schools and colleges of pharmacy in the United States. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0